Authors
Latest:
CAR T Benefits in Cancer Outweigh Potential Risk of Secondary MalignanciesMatthew J. Frigault, MD, MS, discussed what a community oncologist should know about the ongoing FDA investigation of chimeric antigen receptor T-cell therapies.
Latest:
Addressing How to Treat Patients With Advanced Hepatocellular CarcinomaMehmet Akce, MD, discusses how he treats patients with advanced hepatocellular carcinoma in the first-line setting.
Latest:
Expanding the Use of Targeted Therapies in GISTNeeta Somaiah, MD, discusses the expanding role of targeted therapies in patients with gastrointestinal stromal tumor and how these treatments are bolstering later lines of therapy.
Latest:
Insights and Innovative Approaches to Addressing Disparities in Cancer CareCancer care disparities exist for underrepresented groups due to limited access to healthcare, clinical trials, and cultural barriers, but solutions like telemedicine and improved communication are emerging.
Latest:
Future Directions Point to Leveraging ctDNA in LymphomaReid Merryman, MD, discusses the role of minimal residual disease in lymphoma and his presentation on the topic at the 2024 Society of Hematologic Oncology Annual Meeting.
Latest:
Niraparib Results Encourage Somatic Tumor Profiling in Ovarian CancerMatthew Anderson, MD, PhD, discusses how the results with niraparib for patients with advanced ovarian cancer impacts the use of somatic profiling in this patient population.
Latest:
A Deep Dive Into the Evolving Landscape of Prostate CancerIn season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.
Latest:
Challenges Remain in Treating Anaplastic Thyroid CancerYuliya Mikheeva, MD, PhD, discusses the many challenges oncologists face in treating patients with anaplastic thyroid cancer harboring BRAF mutations.
Latest:
Ibrutinib Plus Rituximab Data Surprising in Waldenstrom’s MacroglobulinemiaChristian Buske, MD, discusses surprising findings from the 5-Year follow-up of a randomized phase 3 trial in patients with Waldenström’s macroglobulinemia receiving of ibrutinib plus rituximab or placebo plus rituximab.
Latest:
Questioning When to Start Immunotherapy for Patients With Oncogenic DriversKaren Kelly, MD, discusses how oncogenic drivers affect the use and placement of immunotherapy for patients with lung cancer.
Latest:
Copanlisib and Rituximab Show Efficacy in Follicular LymphomaMark J. Roschewski, MD, discusses the preliminary results of a phase 2 trial of copanlisib and rituximab as treatment of patients with untreated follicular lymphoma.
Latest:
Building a Patient-Centered Ecosystem Leads to Better CareWithin the past decade, there has been a surge in terms such as value-based care, patient-centered care, shared decision-making, and more at the macro level of health care delivery in the US.
Latest:
Closing Perspectives on MM Treatment and CareBrea C. Lipe, MD closes this series highlighting the vast landscape of effective treatments and those on the horizon.
Latest:
Acute Lymphoblastic Leukemia in Older Adults: Is Chemotherapy-Free Treatment in the Future?Investigation of intensive chemotherapy regimens has unfortunately resulted in a lack of improvement in outcomes for patients with acute lymphoblastic leukemia in the second of the bimodal peaks.
Latest:
Future Perspective on Anemia Treatment in LR-MDSSaeed Sadeghi, MD, explores the future treatment landscape for anemia in lower-risk myelodysplastic syndromes (LR-MDS), discussing the impact of emerging therapies on erythropoietin-stimulating agents (ESAs), identifying unmet needs in anemia management, and sharing clinical insights for community oncologists.
Latest:
PARP Inhibition in Metastatic CRPC: The PROfound and TRITON2 StudiesExpert perspectives on the PROfound and TRITON2 studies of olaparib and rucaparib, respectively, in metastatic castration-resistant prostate cancer.
Latest:
Cristian on the 2023 Miami Cancer Institute Oncology Rehabilitation SymposiumAdrian Cristian, MD, discusses the background of the third annual Miami Cancer Institute Oncology Rehabilitation Symposium and provides an overview of some of the topics that were presented this year.
Latest:
Beyond the First-Line: Economides on Advancing Therapies in RCCIn our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Latest:
Skin Toxicity in Cancer Treatment: A Critical Part of Cancer Supportive CareIn contrast to the innovations in cancer treatments that help drive improved survival, there are far fewer innovations targeting toxicities and providing supportive care.
Latest:
Bispecific Antibodies Look Promising in Follicular LymphomaThe use of bispecific antibodies has the potential to revolutionize the management of FL.
Latest:
Phase 3 ADAURA Study Highlights Role for Precision Medicine in EGFR-Positive NSCLCMasahiro Tsuboi, MD, discusses the findings from the phase 3 ADAURA clinical trial of osimertinib as treatment of patients with EGFR-mutated non–small cell lung cancer.
Latest:
MRD Linked to Long-Term Survival With Azacitidine Therapy in AMLAndrew Wei, MBBS, PhD, discusses outcomes related to long-term survival in the QUAZAR AML-001 trial of oral azacitidine in patients with acute myeloid leukemia.
Latest:
Multidisciplinary Approach to Thyroid Cancer ManagementNoah S. Kalman, MD, MBA, discusses how oncologists can determine the best course of action for the treatment and management of a patient with thyroid cancer.
Latest:
Future Directions for NK Cell Platforms in Hematologic MalignanciesJeffrey Miller, MD, discusses what is next to come following an analysis of GTB-3550.
Latest:
Manipulating T Cells to Treat Patients With CancerBruce Feinberg, DO, explains how chimeric antigen receptor T cells were introduced in hematologic malignancies.
Latest:
HR+/HER2- Metastatic Breast Cancer: Future Directions in CareClosing out their program on HR+/HER2- metastatic breast cancer, panelists look toward future evolutions in the treatment landscape.
Latest:
Exploring Novel Combinations in Indolent LymphomasAlthough chemotherapy has represented the standard therapeutic modality for indolent non-Hodgkin lymphoma, monoclonal antibodies, immunomodulatory agents, targeted agents, bispecific antibodies, and cellular therapies are now available.
Latest:
Navigating Unmet Needs in SR/D cGvHDDr Chao provides his insights into the ongoing complexities that clinicians face and shaping a comprehensive understanding of the areas requiring further attention and innovation in cGvHD management.
Latest:
What’s Next for the HER2-Negative Breast Cancer Space?Evanthia Roussos Torres, MD, PhD, discusses the next steps and novel therapies currently showing promise in the HER-2 negative breast cancer space.
